1005 related articles for article (PubMed ID: 25351739)
1. Augmentation of phenotype in a transgenic Parkinson mouse heterozygous for a Gaucher mutation.
Fishbein I; Kuo YM; Giasson BI; Nussbaum RL
Brain; 2014 Dec; 137(Pt 12):3235-47. PubMed ID: 25351739
[TBL] [Abstract][Full Text] [Related]
2. Glucocerebrosidase haploinsufficiency in A53T α-synuclein mice impacts disease onset and course.
Tayebi N; Parisiadou L; Berhe B; Gonzalez AN; Serra-Vinardell J; Tamargo RJ; Maniwang E; Sorrentino Z; Fujiwara H; Grey RJ; Hassan S; Blech-Hermoni YN; Chen C; McGlinchey R; Makariou-Pikis C; Brooks M; Ginns EI; Ory DS; Giasson BI; Sidransky E
Mol Genet Metab; 2017 Dec; 122(4):198-208. PubMed ID: 29173981
[TBL] [Abstract][Full Text] [Related]
3. α-Synuclein accumulation and GBA deficiency due to L444P GBA mutation contributes to MPTP-induced parkinsonism.
Yun SP; Kim D; Kim S; Kim S; Karuppagounder SS; Kwon SH; Lee S; Kam TI; Lee S; Ham S; Park JH; Dawson VL; Dawson TM; Lee Y; Ko HS
Mol Neurodegener; 2018 Jan; 13(1):1. PubMed ID: 29310663
[TBL] [Abstract][Full Text] [Related]
4. Involvement of Gaucher Disease Mutations in Parkinson Disease.
Vilageliu L; Grinberg D
Curr Protein Pept Sci; 2017; 18(7):758-764. PubMed ID: 26965692
[TBL] [Abstract][Full Text] [Related]
5. Glucocerebrosidase modulates cognitive and motor activities in murine models of Parkinson's disease.
Rockenstein E; Clarke J; Viel C; Panarello N; Treleaven CM; Kim C; Spencer B; Adame A; Park H; Dodge JC; Cheng SH; Shihabuddin LS; Masliah E; Sardi SP
Hum Mol Genet; 2016 Jul; 25(13):2645-2660. PubMed ID: 27126635
[TBL] [Abstract][Full Text] [Related]
6. GBA deficiency promotes SNCA/α-synuclein accumulation through autophagic inhibition by inactivated PPP2A.
Du TT; Wang L; Duan CL; Lu LL; Zhang JL; Gao G; Qiu XB; Wang XM; Yang H
Autophagy; 2015; 11(10):1803-20. PubMed ID: 26378614
[TBL] [Abstract][Full Text] [Related]
7. Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations.
Alcalay RN; Levy OA; Waters CC; Fahn S; Ford B; Kuo SH; Mazzoni P; Pauciulo MW; Nichols WC; Gan-Or Z; Rouleau GA; Chung WK; Wolf P; Oliva P; Keutzer J; Marder K; Zhang X
Brain; 2015 Sep; 138(Pt 9):2648-58. PubMed ID: 26117366
[TBL] [Abstract][Full Text] [Related]
8. Glucocerebrosidase and Parkinson disease: Recent advances.
Schapira AH
Mol Cell Neurosci; 2015 May; 66(Pt A):37-42. PubMed ID: 25802027
[TBL] [Abstract][Full Text] [Related]
9. Glucosylsphingosine Promotes α-Synuclein Pathology in Mutant GBA-Associated Parkinson's Disease.
Taguchi YV; Liu J; Ruan J; Pacheco J; Zhang X; Abbasi J; Keutzer J; Mistry PK; Chandra SS
J Neurosci; 2017 Oct; 37(40):9617-9631. PubMed ID: 28847804
[TBL] [Abstract][Full Text] [Related]
10. Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells.
McNeill A; Magalhaes J; Shen C; Chau KY; Hughes D; Mehta A; Foltynie T; Cooper JM; Abramov AY; Gegg M; Schapira AH
Brain; 2014 May; 137(Pt 5):1481-95. PubMed ID: 24574503
[TBL] [Abstract][Full Text] [Related]
11. Glucosylceramide synthase inhibition alleviates aberrations in synucleinopathy models.
Sardi SP; Viel C; Clarke J; Treleaven CM; Richards AM; Park H; Olszewski MA; Dodge JC; Marshall J; Makino E; Wang B; Sidman RL; Cheng SH; Shihabuddin LS
Proc Natl Acad Sci U S A; 2017 Mar; 114(10):2699-2704. PubMed ID: 28223512
[TBL] [Abstract][Full Text] [Related]
12. Advances in GBA-associated Parkinson's disease--Pathology, presentation and therapies.
Barkhuizen M; Anderson DG; Grobler AF
Neurochem Int; 2016 Feb; 93():6-25. PubMed ID: 26743617
[TBL] [Abstract][Full Text] [Related]
13. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease.
Neumann J; Bras J; Deas E; O'Sullivan SS; Parkkinen L; Lachmann RH; Li A; Holton J; Guerreiro R; Paudel R; Segarane B; Singleton A; Lees A; Hardy J; Houlden H; Revesz T; Wood NW
Brain; 2009 Jul; 132(Pt 7):1783-94. PubMed ID: 19286695
[TBL] [Abstract][Full Text] [Related]
14. [GBA mutations and Parkinson's disease].
Wang DX; Xie JX; Song N
Sheng Li Xue Bao; 2018 Jun; 70(3):294-300. PubMed ID: 29926071
[TBL] [Abstract][Full Text] [Related]
15. Lysosomal defects in ATP13A2 and GBA associated familial Parkinson's disease.
Sato S; Li Y; Hattori N
J Neural Transm (Vienna); 2017 Nov; 124(11):1395-1400. PubMed ID: 28894968
[TBL] [Abstract][Full Text] [Related]
16. Parkinson's disease in patients and obligate carriers of Gaucher disease.
Becker JG; Pastores GM; Di Rocco A; Ferraris M; Graber JJ; Sathe S
Parkinsonism Relat Disord; 2013 Jan; 19(1):129-31. PubMed ID: 22940477
[TBL] [Abstract][Full Text] [Related]
17. Gaucher-Associated Parkinsonism.
Li Y; Li P; Liang H; Zhao Z; Hashimoto M; Wei J
Cell Mol Neurobiol; 2015 Aug; 35(6):755-61. PubMed ID: 25820783
[TBL] [Abstract][Full Text] [Related]
18. D409H GBA1 mutation accelerates the progression of pathology in A53T α-synuclein transgenic mouse model.
Kim D; Hwang H; Choi S; Kwon SH; Lee S; Park JH; Kim S; Ko HS
Acta Neuropathol Commun; 2018 Apr; 6(1):32. PubMed ID: 29703245
[TBL] [Abstract][Full Text] [Related]
19. Heterozygous GBA D409V and ATP13a2 mutations do not exacerbate pathological α-synuclein spread in the prodromal preformed fibrils model in young mice.
Johnson ME; Bergkvist L; Stetzik L; Steiner JA; Meyerdirk L; Schulz E; Wolfrum E; Luk KC; Wesson DW; Krainc D; Brundin P
Neurobiol Dis; 2021 Nov; 159():105513. PubMed ID: 34536552
[TBL] [Abstract][Full Text] [Related]
20. Gaucher disease: complexity in a "simple" disorder.
Sidransky E
Mol Genet Metab; 2004; 83(1-2):6-15. PubMed ID: 15464415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
